A Phase 1, Open-label Study to Evaluate the Mass Balance of Orally Administered FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2017
Price : $35 *
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Taiho Pharmaceutical
- 02 Feb 2016 Planned End Date changed from 1 Oct 2015 to 1 Feb 2016 as per ClinicalTrials.gov record.
- 28 Jul 2015 Planned End Date changed from 1 Apr 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov
- 02 Jun 2015 Interim results in 8 patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology.